Tarsus Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Tarsus Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 7 completed early-phase tilt top decile by trial count

Tarsus Pharmaceuticals: 9 sponsored US clinical trials, none currently recruiting.

Tarsus Pharmaceuticals sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 2 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Demodectic Blepharitis, with 1 trials.

Top-decile sponsor footprint

Tarsus Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2

A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure

NCT07562087
ACTIVE NOT RECRUITING Phase 2

Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex

NCT06054217
COMPLETED Phase 4

Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers

NCT06182358
COMPLETED Phase 1

Study to Evaluate the Food Effect of TP-05 in Healthy Participants

NCT05720364
COMPLETED Phase 2

A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05

NCT05387083
COMPLETED Phase 2

Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD

NCT05454956
COMPLETED Phase 1

A Pharmacokinetic Study of TP-05 in Healthy Subjects

NCT05138796
COMPLETED Phase 3

Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

NCT04784091
COMPLETED Phase 2

Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

NCT04475432

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 5
Phase 3 1
Phase 4 1

Therapeutic Areas

Demodectic Blepharitis 1
Demodex Infestation of Eyelid 1
Meibomian Gland Dysfunction 1
Blepharitis 1
Demodex Blepharitis 1
Healthy 1

How the Tarsus Pharmaceuticals early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 7 completed (78%).

Phase mix: 2 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Demodectic Blepharitis (1 trial), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Tarsus Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Tarsus Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Tarsus Pharmaceuticals4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Tarsus Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Tarsus Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Tarsus Pharmaceuticals page

9 registered trials is a research-attention snapshot, not an endorsement of Tarsus Pharmaceuticals or any single study.

  • None of Tarsus Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Demodectic Blepharitis is the condition Tarsus Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Demodectic Blepharitis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Tarsus Pharmaceuticals pipeline card: 9 registered trials from official public datasets.Report a data error.